Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.64 |
| ▸ | CA1 | P00915 | 10/20 | 0.64 |
| ▸ | CA12 | O43570 | 6/20 | 0.64 |
| ▸ | CA9 | Q16790 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | ATIC | P31939 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13196624 | 0.93 | CA2 (0.74) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL2762384 | 0.89 | CA2 (0.65) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL2762150 | 0.86 | NAMPT (0.62) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL2762125 | 0.84 | CA2 (0.60) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL2762124 | 0.84 | CA2 (0.58) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL2762003 | 0.83 | MAPT (0.68) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL6078481 | 0.82 | MEN1 (0.60) | KMT2AMEN1ALDH1A1MAPTATIC | |
| SCHEMBL6284564 | 0.80 | MAPT (0.72) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL6280127 | 0.80 | CA2 (0.60) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL671898 | 0.79 | CA12 (1.00) | CA2CA1CA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | disclosed |
| EP-2391601-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086177-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | 4SC AG (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | SLC14A1, UTS2R, UROD | CA2 2340/4885CA1 4272/4885CA12 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.